Skip to Main Content

An official website of the United States government

About this Publication
Title
Body mass index and glioma risk: A prospective multicenter study.
Pubmed ID
36105407 (View this publication on the PubMed website)
Digital Object Identifier
Publication
Front Endocrinol (Lausanne). 2022; Volume 13: Pages 933921
Authors
Shao C, Tang H, Wang X, He J, Wang P, Wu N
Affiliations
  • Department of Neurosurgery, Chongqing General Hospital, Chongqing, China.
  • Department of Neurosurgery, Nanchong Central Hospital, The Second Clinical Medical College, North Sichuan Medical College, Nanchong, China.
Abstract

BACKGROUND: The association between glioma risk and body mass index (BMI) remains obscure.

METHODS: This study aimed to assess the association between glioma risk and BMI in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cox proportional hazards regression was used to calculate the hazard ratios (HRs) and 95% confidence intervals (CIs).

RESULTS: The onset of a total of 269 gliomas was observed during a median follow-up period of 12.04 years. Compared with the normal weight, overweight (HR: 1.05; 95% CI: 0.80, 1.39) and obesity (HR: 0.91; 95% CI: 0.56, 1.39) were not significantly associated with glioma risk. Further analysis showed a nonlinear relationship between glioma risk and BMI in men but not women. The multivariable-adjusted HRs per unit increase in BMI were 0.94 (95% CI: 0.89, 1.00; P = 0.037) in men with BMI >25 kg/m2 and 1.16 (95% CI: 0.98, 1.38; P = 0.075) in men with BMI <25 kg/m2.

CONCLUSION: The present data provide evidence that there may be a nonlinear association between BMI and glioma risk in men. The risk of glioma decreased with increasing BMI among men with BMI >25 kg/m2. Future studies are needed to validate our observation.

Related CDAS Studies
Related CDAS Projects